2F-Viminol, a pyrrole-derived opioid analgesic, originally emerged from the research efforts of the pharmaceutical company Zambon during the 1960s. It boasts roughly double the potency of its precursor compound, viminol. However, unlike viminol, 2F-viminol has not advanced through clinical trials or gained approval for medical purposes. Instead, it has made its way into the realm of designer drugs, with its first detection occurring in Sweden in 2019.
This substance belongs to a category of structurally unique opioid agonists that have surfaced on the grey market for designer drugs. This trend emerged after broad regulations on fentanyl analogs were instituted in China in 2015. It’s worth noting that, due to concerns over its safety and potential misuse, 2F-Viminol was prohibited in Sweden in August 2019 and in Latvia in November 2019.

IUPAC name
CAS Number63880-43-3 
PubChem CID57419227
Chemical and physical data
Molar mass346.490 g·mol−1


  • What is 2F-Viminol?
  • 2F-Viminol is an opioid analgesic drug with a pyrrole-derived structure. It was originally developed by the pharmaceutical company Zambon in the 1960s.
  • How does 2F-Viminol compare to its precursor, viminol?
  • 2F-Viminol is approximately twice as potent as viminol, the parent compound. However, it has yet to undergo clinical trials and needs approval for medical use.
  • Why is 2F-Viminol considered a designer drug?
  • 2F-Viminol is categorized as a designer drug because it has not been approved for medical purposes. Instead, it is available on the grey market for recreational or non-medical use.
  • When was 2f-viminol first identified as a designer drug?
  • 2F-Viminol was first identified as a designer drug in Sweden in 2019.
  • Why have some countries made 2F-Viminol illegal?
  • Due to concerns about the safety and potential misuse of 2F-Viminol, some countries, such as Sweden and Latvia, have implemented legal restrictions and made it illegal.
  • What are the potential risks associated with 2F-Viminol use?
  • The safety and risks associated with 2F-Viminol are not well-documented, as it has yet to undergo formal clinical testing. Users should be cautious and aware of potential adverse effects and legal implications.
  • Where can I find more information about 2F-Viminol?
  • To access more comprehensive information about 2F-Viminol, consider referring to scientific literature, research studies, and reliable sources. It’s essential to stay informed about its legal status and potential health risks in your region.


  1. “Prohibition of Harmful Health Products.” Published in the Swedish Code of Statutes on July 4, 2019. This ordinance came into effect on August 6, 2019.
  2. Bao Y, Meng S, Shi J, Lu L (July 2019). “Regulation of Compounds Related to Fentanyl in China.” Published in The Lancet Psychiatry, Volume 6, Issue 7, Page e15. DOI: 10.1016/S2215-0366(19)30218-4. PMID: 31230685.
  3. “SPKC Bans 2F-Viminol, Furanyl UF-17, and Products Containing Them.” [SPKC nosaka aizliegumu vielām 2F-viminol, furanyl UF – 17 un to saturošiem izstrādājumiem]. Published by the Center for Disease Prevention and Control (Slimību profilakses un kontroles centrs) in Latvian on November 6, 2019.

Leave a Comment

Your email address will not be published. Required fields are marked *